Literature DB >> 26227906

The Role of Cdk5 in Alzheimer's Disease.

Shu-Lei Liu1, Chong Wang1, Teng Jiang2, Lan Tan3, Ang Xing4, Jin-Tai Yu5,6.   

Abstract

Alzheimer's disease (AD) is known as the most fatal chronic neurodegenerative disease in adults along with progressive loss of memory and other cognitive function disorders. Cyclin-dependent kinase 5 (Cdk5), a unique member of the cyclin-dependent kinases (Cdks), is reported to intimately associate with the process of the pathogenesis of AD. Cdk5 is of vital importance in the development of CNS and neuron movements such as neuronal migration and differentiation, synaptic functions, and memory consolidation. However, when neurons suffer from pathological stimuli, Cdk5 activity becomes hyperactive and causes aberrant hyperphosphorylation of various substrates of Cdk5 like amyloid precursor protein (APP), tau and neurofilament, resulting in neurodegenerative diseases like AD. Deregulation of Cdk5 contributes to an array of pathological events in AD, ranging from formation of senile plaques and neurofibrillary tangles, synaptic damage, mitochondrial dysfunction to cell cycle reactivation as well as neuronal cell apoptosis. More importantly, an inhibition of Cdk5 activity with inhibitors such as RNA inference (RNAi) could protect from memory decline and neuronal cell loss through suppressing β-amyloid (Aβ)-induced neurotoxicity and tauopathies. This review will briefly describe the above-mentioned possible roles of Cdk5 in the physiological and pathological mechanisms of AD, further discussing recent advances and challenges in Cdk5 as a therapeutic target.

Entities:  

Keywords:  Alzheimer’s disease; Aβ; Cdk5; Pathogenesis; Tau; Therapy

Mesh:

Substances:

Year:  2015        PMID: 26227906     DOI: 10.1007/s12035-015-9369-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  134 in total

Review 1.  Alzheimer's disease.

Authors:  Henry W Querfurth; Frank M LaFerla
Journal:  N Engl J Med       Date:  2010-01-28       Impact factor: 91.245

2.  Valproic acid downregulates Cdk5 activity via the transcription of the p35 mRNA.

Authors:  Miyuki Takahashi; Manami Ishida; Taro Saito; Toshio Ohshima; Shin-Ichi Hisanaga
Journal:  Biochem Biophys Res Commun       Date:  2014-04-19       Impact factor: 3.575

3.  The kinase activity of EphA4 mediates homeostatic scaling-down of synaptic strength via activation of Cdk5.

Authors:  Yi-Rong Peng; Zai-Hua Hou; Xiang Yu
Journal:  Neuropharmacology       Date:  2012-11-02       Impact factor: 5.250

4.  Isoflurane-induced neuroapoptosis in the neonatal rhesus macaque brain.

Authors:  Ansgar M Brambrink; Alex S Evers; Michael S Avidan; Nuri B Farber; Derek J Smith; Xuezhao Zhang; Gregory A Dissen; Catherine E Creeley; John W Olney
Journal:  Anesthesiology       Date:  2010-04       Impact factor: 7.892

5.  Membrane association facilitates degradation and cleavage of the cyclin-dependent kinase 5 activators p35 and p39.

Authors:  Seiji Minegishi; Akiko Asada; Shinya Miyauchi; Takahiro Fuchigami; Taro Saito; Shin-Ichi Hisanaga
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

6.  The roles of Cdk5-mediated subcellular localization of FOXO1 in neuronal death.

Authors:  Jiechao Zhou; Huifang Li; Xiaoping Li; Guanyun Zhang; Yaqiong Niu; Zengqiang Yuan; Karl Herrup; Yun-Wu Zhang; Guojun Bu; Huaxi Xu; Jie Zhang
Journal:  J Neurosci       Date:  2015-02-11       Impact factor: 6.167

7.  LMTK1/AATYK1 is a novel regulator of axonal outgrowth that acts via Rab11 in a Cdk5-dependent manner.

Authors:  Tetsuya Takano; Mineko Tomomura; Nozomu Yoshioka; Koji Tsutsumi; Yukichi Terasawa; Taro Saito; Hitoshi Kawano; Hiroyuki Kamiguchi; Mitsunori Fukuda; Shin-ichi Hisanaga
Journal:  J Neurosci       Date:  2012-05-09       Impact factor: 6.167

8.  Early postnatal in vivo gliogenesis from nestin-lineage progenitors requires cdk5.

Authors:  David Petrik; Sanghee Yun; Sarah E Latchney; Sohail Kamrudin; Junie A LeBlanc; James A Bibb; Amelia J Eisch
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

9.  Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity.

Authors:  Dohoon Kim; Christopher L Frank; Matthew M Dobbin; Rachel K Tsunemoto; Weihong Tu; Peter L Peng; Ji-Song Guan; Byung-Hoon Lee; Lily Y Moy; Paola Giusti; Nisha Broodie; Ralph Mazitschek; Ivanna Delalle; Stephen J Haggarty; Rachael L Neve; Youming Lu; Li-Huei Tsai
Journal:  Neuron       Date:  2008-12-10       Impact factor: 17.173

10.  Synaptic NMDA receptor stimulation activates PP1 by inhibiting its phosphorylation by Cdk5.

Authors:  Hailong Hou; Lu Sun; Benjamin A Siddoway; Ronald S Petralia; Hongtian Yang; Hua Gu; Angus C Nairn; Houhui Xia
Journal:  J Cell Biol       Date:  2013-11-04       Impact factor: 10.539

View more
  63 in total

1.  CDK5-Mediated Phosphorylation-Dependent Ubiquitination and Degradation of E3 Ubiquitin Ligases GP78 Accelerates Neuronal Death in Parkinson's Disease.

Authors:  Qingzhi Wang; Fengjuan Jiao; Pei Zhang; Jianguo Yan; Zheng Zhang; Feng He; Qian Zhang; Zexi Lv; Xiang Peng; Hongwei Cai; Bo Tian
Journal:  Mol Neurobiol       Date:  2017-05-20       Impact factor: 5.590

2.  Cognition in Epilepsy: ΔFosB Takes Center Stage (and May Star in the Prologue).

Authors:  Christina Gross
Journal:  Epilepsy Curr       Date:  2018 Sep-Oct       Impact factor: 7.500

Review 3.  Functional analyses of major cancer-related signaling pathways in Alzheimer's disease etiology.

Authors:  Jianping Guo; Ji Cheng; Brian J North; Wenyi Wei
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-07-08       Impact factor: 10.680

4.  Cholinergic Differentiation of Human Neuroblastoma SH-SY5Y Cell Line and Its Potential Use as an In vitro Model for Alzheimer's Disease Studies.

Authors:  Liana M de Medeiros; Marco A De Bastiani; Eduardo P Rico; Patrícia Schonhofen; Bianca Pfaffenseller; Bianca Wollenhaupt-Aguiar; Lucas Grun; Florência Barbé-Tuana; Eduardo R Zimmer; Mauro A A Castro; Richard B Parsons; Fábio Klamt
Journal:  Mol Neurobiol       Date:  2019-04-29       Impact factor: 5.590

5.  Nitazoxanide, an anti-parasitic drug, efficiently ameliorates learning and memory impairments in AD model mice.

Authors:  Lei Fan; Xiao-Xia Qiu; Zhi-Yuan Zhu; Jian-Lu Lv; Jian Lu; Fei Mao; Jin Zhu; Jia-Ying Wang; Xiao-Wei Guan; Jing Chen; Jin Ren; Ji-Ming Ye; Yong-Hua Zhao; Jian Li; Xu Shen
Journal:  Acta Pharmacol Sin       Date:  2019-04-18       Impact factor: 6.150

6.  Transcriptomic and epigenomic analyses explore the potential role of H3K4me3 in neomycin-induced cochlear Lgr5+ progenitor cell regeneration of hair cells.

Authors:  Xiangyu Ma; Shasha Zhang; Shijie Qin; Jiamin Guo; Jia Yuan; Ruiying Qiang; Shan Zhou; Wei Cao; Jianming Yang; Fei Ma; Renjie Chai
Journal:  Hum Cell       Date:  2022-06-06       Impact factor: 4.174

7.  Dexmedetomidine Ameliorates Postoperative Cognitive Dysfunction in Aged Mice.

Authors:  Xiaolan Xie; Zhiwen Shen; Chuwen Hu; Kun Zhang; Mingyan Guo; Fei Wang; Kai Qin
Journal:  Neurochem Res       Date:  2021-06-23       Impact factor: 3.996

8.  Disruption of microglia histone acetylation and protein pathways in mice exhibiting inflammation-associated depression-like symptoms.

Authors:  Sandra L Rodriguez-Zas; Cong Wu; Bruce R Southey; Jason C O'Connor; Scott E Nixon; Robmay Garcia; Cynthia Zavala; Marcus Lawson; Robert H McCusker; Elena V Romanova; Jonathan V Sweedler; Keith W Kelley; Robert Dantzer
Journal:  Psychoneuroendocrinology       Date:  2018-06-30       Impact factor: 4.905

Review 9.  Tau-targeting therapies for Alzheimer disease.

Authors:  Erin E Congdon; Einar M Sigurdsson
Journal:  Nat Rev Neurol       Date:  2018-07       Impact factor: 42.937

Review 10.  Reduced brain insulin signaling: A seminal process in Alzheimer's disease pathogenesis.

Authors:  George S Bloom; John S Lazo; Andrés Norambuena
Journal:  Neuropharmacology       Date:  2017-09-29       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.